Les meilleurs doctors en Israël pour votre Immunothérapie - TOP 22 des médecins

Le Professeur Merimsky dirige la recherche en immunothérapie au Centre médical Sourasky, avec des décennies d'expertise dans les traitements avancés du cancer.

• Chef de l'Unité d'oncologie des tissus mous et des os
• Membre de la faculté du groupe Sarcome de la Société Européenne d'Oncologie Médicale (ESMO)
• Vastes collaborations de recherche avec l'Institut Weizmann et le Centre de recherche médicale Felsenstein
• Plus de 20 ans d'expérience dans la pratique clinique en oncologie

Le Dr Pelles Sharon est spécialisé en immunothérapie, y compris les traitements comme Keytruda, au Sourasky Medical Center (Ichilov).

• Expérimenté dans divers traitements contre le cancer, avec un accent sur l'immunothérapie
• A contribué à la recherche clinique sur les attitudes des patients oncologiques envers les essais
• Effectue des procédures avancées comme la Chimiothérapie Intrapéritonéale Hyperthermique (HIPEC)
• Propose des thérapies ciblées parallèlement aux traitements traditionnels contre le cancer

Le Dr Sarid, oncologue senior à Ichilov, est spécialisé en thérapie biologique du cancer et a publié plus de 30 articles sur les traitements contre le cancer.

• Plus de 15 ans d'expérience en tant qu'oncologue senior au Centre Médical Sourasky
• Investigateur principal dans le cadre d'essais cliniques pour les thérapies contre le cancer
• Formation spécialisée en uro-oncologie à l'Université d'Oxford
• Membre de l'ESMO et de l'ASCO – organisations d'oncologie de premier plan

Spécialiste en gynécologie oncologique et radiothérapie – Le Dr Sapra apporte une expertise ciblée aux cas d'immunothérapie au Centre médical Sourasky.

• Se spécialise dans les traitements d'oncologie gynécologique
• Expertise dans les applications de radiothérapie
• Exerce ses fonctions dans un centre médical de premier plan en Israël

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Le Dr Ido Wolf dirige la Division d'oncologie médicale au Centre médical Sourasky, avec une spécialisation en immunothérapie.

• Chef de la Division d'oncologie médicale au Centre médical Sourasky
• Diplôme de l'Université Ben Gourion du Néguev
• Expérience en oncologie, en médecine interne et au sein d'unités médicales de l'armée

Direction d'essais d'immunothérapie au centre médical Sourasky – Le Dr Raphael est spécialisé dans le profilage génomique et les injections intratumorales pour les cancers thoraciques.

• Investigateur principal pour de multiples essais cliniques d'immunothérapie, y compris des études sur le pembrolizumab
• Expert en biopsies liquides et en séquençage du répertoire des lymphocytes T pour la réponse au traitement
• Modérateur du comité moléculaire des tumeurs (Molecular Tumor Board) pour la Société israélienne du cancer du poumon
• Honoré comme enseignant exceptionnel à la faculté de médecine de l'Université de Tel-Aviv
• Formation spécialisée (Fellowship) en innovation et entrepreneuriat en médecine et technologies de la santé

Directeur du Service de neuro-oncologie, avec plus de 25 ans de spécialisation dans les tumeurs cérébrales. Le Dr Blumenthal dirige les programmes d'immunothérapie au Centre médical Sourasky.

• Formation effectuée au Memorial Sloan-Kettering Cancer Center
• Ancien directeur de l'Institut du cancer Huntsman
• Spécialisé dans les traitements avancés en neuro-oncologie

Directeur de l'hospitalisation en oncologie au Centre médical de Tel Aviv – Le Dr Stepfansky dirige la recherche et le traitement en immunothérapie à Ichilov.

• Plus de 15 ans de spécialisation en oncologie
• Chercheur principal dans les essais cliniques de phase 1 à 3
• Formation reçue au Centre médical de Tel Aviv
• Expert en médecine interne et en oncologie

Le Dr Fredi Aviv apporte 31 ans d'expérience spécialisée en oncohématologie au Centre Médical Sourasky (Clinique Ichilov).

• Spécialisé dans les traitements d'immunothérapie pour les cancers du sang
• Vaste expérience des hémopathies malignes complexes
• Exerce dans l'un des principaux centres médicaux d'Israël

Le Dr Dror Levin est un spécialiste de premier plan en hématologie et oncologie pédiatriques. Il est spécialisé dans le traitement du cancer des os (sarcome) chez les enfants au Centre médical Sourasky de Tel Aviv.

• Directeur du département d'hématologie et d'oncologie pédiatriques au Centre médical Sourasky
• Spécialisé en hématologie et oncologie pédiatriques au Centre médical pour enfants Schneider
• Membre de l'Association israélienne d'hémato-oncologie pédiatrique (ISPHO)
• Formation en oncologie des os et des tissus mous à l'Institut orthopédique Rizzoli en Italie

Le Dr Amir est spécialisé en thérapie ciblée pour le cancer du sein utilisant Keytruda (Pembolizumab), et compte plus de 30 présentations lors de réunions scientifiques.

• Récipiendaire de plusieurs prix, y compris le Prix ESMO de recherche translationnelle sur le cancer du sein (ESMO Breast Cancer Translational Research Award)
• Membre de la Société européenne d'oncologie médicale (ESMO)
• Fellowship en recherche sur le cancer du sein à l'Université Emory
• Plus de 15 ans d'expérience en oncologie

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

La Professeure Myriam Ben Arush est une spécialiste internationalement reconnue en oncologie pédiatrique et en greffe de moelle osseuse au Centre médical Rambam.

• Directrice de la Division Pédiatrique à l'Hôpital pour Enfants Ruth Rappaport
• Récipiendaire du Chevalier de la Légion d'Honneur en France
• Nommée l'une des médecins les plus attentionnés au monde par l'Association Médicale Mondiale
• Membre du Children's Oncology Group aux États-Unis